 Daclatasvir is a recently approved anti-HCV agent that is a cytochrome P450 3a CYP3A substrate but does not affect CYP3A itself. It is also a moderate inhibitor of various membrane transporters such as organic anion-transporting polypeptide 1B1 OATP1B1 , p-glycoprotein P-gP, and organic cation transporter OCT 1 and 2. 